Novo Nordisk, a Danish pharmaceutical company, has launched a new initiative to provide access to its injectable drug Wegovy (semaglutide) in Brazilian public health units, specifically through the Unified Health System (SUS). This program, announced on Wednesday, is part of a global effort conducted in collaboration with the Danish government and aims to offer the drug in conjunction with a multidisciplinary care protocol for at least two years. The initiative is set to include three healthcare facilities in Brazil, focusing on comprehensive support for patients receiving treatment.

The three involved facilities include the Grupo Hospitalar Conceição (GHC) in Porto Alegre, a federal health institution, and the Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione (Iede) located in Rio de Janeiro. Additionally, a third municipal health center is yet to be determined. While Novo Nordisk is optimistic about the partnerships, the Foundation for Health of the State of Rio de Janeiro, which oversees the Iede, has stated that there is currently no formal agreement with the pharmaceutical company. They also highlighted their experience using liraglutide for outpatient treatment for a number of patients previously.

This initiative has significant implications for public health in Brazil, especially given the challenges related to obesity and chronic illnesses. The introduction of Wegovy into public health units could enhance the treatment landscape for affected individuals. However, the absence of a confirmed partnership with the Iede raises questions about the effectiveness and reach of the program, impacting potential patients who might benefit from these treatments. The next steps will be crucial in determining how these collaborations unfold and the overall impact on Brazil's healthcare system.